Physician profile
John M Pierce
NPI 1295762722
$1,891.69
in general payments reported to CMS, 2019-2025
24 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $209 · 2021: $183 · 2022: $12.10 · 2023: $169 · 2024: $270 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $384.42 | 2019-2025 | Lifevest |
| Ucb, INC. | $154.54 | 2019-2025 | Bimzelx |
| Janssen Pharmaceuticals, INC | $152.13 | 2019-2024 | Xarelto |
| Pfizer INC. | $143.72 | 2020-2024 | |
| Lilly USA, LLC | $135.44 | 2020-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $121.83 | 2025 | Airsupra |
| Novo Nordisk INC | $118.76 | 2019-2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $99.94 | 2021-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $89.58 | 2019-2025 | |
| Abbvie INC. | $87.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.08 | 2021 | |
| Alexion Pharmaceuticals, INC. | $49.52 | 2020-2025 | Ultomiris, Strensiq |
| Edwards Lifesciences Corporation | $46.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.71 | 2020-2025 | Camzyos |
| Mayne Pharma Commercial LLC | $31.82 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $25.59 | 2019 | |
| Portola Pharmaceuticals, LLC | $23.92 | 2019 | |
| La Jolla Pharmaceutical Company | $23.43 | 2024 | Xerava |
| Sanofi-Aventis U.S. LLC | $18.21 | 2019 | |
| Mylan Specialty L.P. | $17.22 | 2019 | |
| Dynavax Technologies Corporation | $17.07 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $12.10 | 2022 | |
| Shire North American Group INC | $11.82 | 2019 | |
| Corium, LLC | $11.33 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.